ATE324104T1 - Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung - Google Patents

Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung

Info

Publication number
ATE324104T1
ATE324104T1 AT02026576T AT02026576T ATE324104T1 AT E324104 T1 ATE324104 T1 AT E324104T1 AT 02026576 T AT02026576 T AT 02026576T AT 02026576 T AT02026576 T AT 02026576T AT E324104 T1 ATE324104 T1 AT E324104T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
controlled release
release pharmaceutical
containing mesalazine
Prior art date
Application number
AT02026576T
Other languages
English (en)
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324104(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Application granted granted Critical
Publication of ATE324104T1 publication Critical patent/ATE324104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02026576T 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung ATE324104T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001316A ITMI991316A1 (it) 1999-06-14 1999-06-14 Composizioni farmaceutiche orali a rilascio modificato di mesalazina

Publications (1)

Publication Number Publication Date
ATE324104T1 true ATE324104T1 (de) 2006-05-15

Family

ID=11383159

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02026576T ATE324104T1 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung
AT00935194T ATE235234T1 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00935194T ATE235234T1 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung

Country Status (18)

Country Link
US (1) US6773720B1 (de)
EP (2) EP1198226B1 (de)
JP (2) JP4727875B2 (de)
CN (2) CN100448448C (de)
AT (2) ATE324104T1 (de)
AU (1) AU5077200A (de)
CA (1) CA2377299C (de)
DE (2) DE60001835T2 (de)
DK (2) DK1198226T3 (de)
ES (2) ES2262749T3 (de)
HK (1) HK1046247B (de)
IT (1) ITMI991316A1 (de)
MX (1) MXPA01012888A (de)
NO (1) NO329402B1 (de)
PT (2) PT1198226E (de)
RU (1) RU2245148C2 (de)
TR (1) TR200200561T2 (de)
WO (1) WO2000076481A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
WO2004093883A2 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
WO2005065673A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
EP1722630A4 (de) 2004-01-20 2009-05-27 Richard F Harty Zusammensetzungen und verfahren zur behandlung von entzündungskrankheiten
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
MX2009000658A (es) 2006-07-19 2009-01-30 Univ Texas Preparaciones de fosfolipidos y componentes farmaceuticos que contienen acido 5-amino salicilico para el tratamiento de una enfermedad inflamatoria del intestino delgado.
CA2662428A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
WO2008033125A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
PT2099446E (pt) 2006-11-17 2013-02-13 Shire Dev Inc Método de tratamento de doença inflamatória intestinal
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2488163A1 (de) 2009-10-16 2012-08-22 Ranbaxy Laboratories Limited Pharmazeutische zusammensetzung aus mesalamin mit verzögerter freisetzung
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
EP2425826A1 (de) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazin-Tablette mit verbesserter Auflösung
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
EP2468264A1 (de) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Orale pharmazeutische Tablette zur gesteuerten Abgabe von Mesalazin und Verfahren zu deren Erhalt
LT2661266T (lt) 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
CN110693867A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
AU2013229990B2 (en) * 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
WO2013144176A1 (en) * 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2722058A1 (de) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Orale Feststoffzusammensetzung mit Farbstoffen für die Verwendung bei der endoskopischen Diagnose
HK1214966A1 (zh) 2013-01-05 2016-08-12 Anji Pharmaceuticals Inc. 包含雙胍的延遲釋放組合物
CA2901166C (en) * 2013-02-22 2020-03-24 Zeria Pharmaceutical Co., Ltd. Enteric coated tablet
US9763887B2 (en) 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CN104922090B (zh) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 美沙拉秦肠溶缓释微丸
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
JP2019535794A (ja) 2016-11-28 2019-12-12 コスモ・テクノロジーズ・リミテツド 色素を含有する固体経口組成物
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3501503A1 (de) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Feste verabreichungszusammensetzung
EP3662895A1 (de) 2018-12-07 2020-06-10 Tillotts Pharma AG Verfahren zur herstellung von reduzierenden zuckerfreien 5-asa-tablettenkernen
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
CN112587506A (zh) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 一种用于制备美沙拉嗪肠溶缓释胶囊的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
JPH02282323A (ja) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
JPH0624962A (ja) * 1992-07-09 1994-02-01 Green Cross Corp:The 腸溶徐放性製剤
DE69332291T2 (de) * 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
WO1998026767A2 (en) * 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions

Also Published As

Publication number Publication date
TR200200561T2 (tr) 2002-06-21
ES2262749T3 (es) 2006-12-01
CN1720919A (zh) 2006-01-18
EP1287822A3 (de) 2003-03-19
DE60001835D1 (de) 2003-04-30
EP1198226B1 (de) 2003-03-26
DE60027608T2 (de) 2007-04-26
DK1198226T3 (da) 2003-07-21
ES2194732T3 (es) 2003-12-01
NO329402B1 (no) 2010-10-11
HK1046247B (zh) 2006-04-07
MXPA01012888A (es) 2002-07-30
EP1287822B1 (de) 2006-04-26
CN100448448C (zh) 2009-01-07
NO20016107L (no) 2002-02-11
JP5235839B2 (ja) 2013-07-10
DE60001835T2 (de) 2003-11-13
JP2010024241A (ja) 2010-02-04
ITMI991316A0 (it) 1999-06-14
DK1287822T3 (da) 2006-08-28
JP2003501458A (ja) 2003-01-14
DE60027608D1 (de) 2006-06-01
CN1217665C (zh) 2005-09-07
EP1198226A1 (de) 2002-04-24
NO20016107D0 (no) 2001-12-14
HK1085669A1 (zh) 2006-09-01
US6773720B1 (en) 2004-08-10
PT1198226E (pt) 2003-07-31
CN1355694A (zh) 2002-06-26
JP4727875B2 (ja) 2011-07-20
AU5077200A (en) 2001-01-02
ATE235234T1 (de) 2003-04-15
ITMI991316A1 (it) 2000-12-14
PT1287822E (pt) 2006-07-31
EP1287822A2 (de) 2003-03-05
HK1046247A1 (en) 2003-01-03
WO2000076481A1 (en) 2000-12-21
CA2377299A1 (en) 2000-12-21
RU2245148C2 (ru) 2005-01-27
CA2377299C (en) 2009-05-12

Similar Documents

Publication Publication Date Title
DE60001835D1 (de) Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
DE69523438D1 (de) Orale metoprolol-dosisform des typs "einmal täglich"
RU2002102701A (ru) Стабильная пероральная образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
EP2322146A3 (de) Mikrokapselformulierung mit zwei pharmazeutischen Wirkstoffen
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE79538T1 (de) Dispergierbare zubereitung.
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
DE69710121D1 (de) Pharmazeutische Zusammensetzung aus stabilisierten lipophilen Matrizen mit kontrollierter Wirkstofffreisetzung
AR034435A1 (es) Agentes terapeuticos.
ES2169980B1 (es) Microcapsulas para la liberacion prolongada de farmacos.
FI922698A0 (fi) Foerbaettrade acetazolamidpreparat.
DE60029946D1 (de) Arzneimittel gegen glomerulosclerose
ITMI20000972A0 (it) Formulazioni farmaceutiche, a rilascio modificato, con elevata biodisponibilita', contenenti principi attivi ad attivita' antibiotica.
CO4910116A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles
DE60115450D1 (de) Pirlindolhydrochlorid-Matrixformulierungen mit verlängerter Wirkstofffreigabe
PA8531801A1 (es) Formulaciones estabilizadas que comprenden composiciones hidroliticamente inestables

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1287822

Country of ref document: EP